Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:39
05/22/20
05/22
12:39
05/22/20
12:39
NVDA

Nvidia

$359.38 /

+8.37 (+2.38%)

, HPE

HP Enterprise

$9.21 /

-1.14 (-11.01%)

, DE

Deere

$144.73 /

+1.92 (+1.34%)

, IBM

IBM

$117.75 /

-1.37 (-1.15%)

, BABA

Alibaba

$201.61 /

-10.39 (-4.90%)

, SPLK

Splunk

$184.26 /

+20.99 (+12.86%)

, RAMP

LiveRamp

$48.51 /

+9.81 (+25.35%)

, ELF

e.l.f. Beauty

$16.46 /

+1.9 (+13.05%)

, AMRN

Amarin

$7.16 /

-0.125 (-1.72%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

, ICPT

Intercept

$79.55 /

-12 (-13.11%)

The S&P and Dow are a…

Open Full Text

ShowHide Related Items >><<
SPLK Splunk
$184.26 /

+20.99 (+12.86%)

RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

05/22/20 JPMorgan
Nvidia price target raised to $405 from $305 at JPMorgan
05/22/20 Rosenblatt
Nvidia price target raised to $400 from $340 at Rosenblatt
05/22/20 Raymond James
Nvidia price target raised to $370 from $330 at Raymond James
05/22/20 Craig-Hallum
Nvidia price target raised to $335 from $300 at Craig-Hallum
HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 Raymond James
HP Enterprise downgraded to Market Perform from Outperform at Raymond James
05/22/20 Morgan Stanley
Second quarter 'not yet a bottom' for HP Enterprise, says Morgan Stanley
05/22/20 Citi
HP Enterprise earnings call leaves more questions than answers, says Citi
DE Deere
$144.73 /

+1.92 (+1.34%)

05/22/20 Goldman Sachs
Goldman Sachs sees Deere shares outperforming today after earnings
05/20/20 Citi
Deere price target lowered to $145 from $155 at Citi
04/20/20 OTR Global
Farm Equipment Manufacturers downgraded to Negative at OTR Global
04/20/20 Stephens
USDA aid package a positive for Large Ag, says Stephens
IBM IBM
$117.75 /

-1.37 (-1.15%)

04/21/20 Morgan Stanley
Krishna years away from returning IBM to sustainable growth, says Morgan Stanley
04/21/20 Wedbush
IBM price target lowered to $140 from $155 at Wedbush
04/17/20 BMO Capital
IBM price target lowered to $135 from $155 at BMO Capital
04/15/20 Credit Suisse
IBM price target lowered to $150 from $173 at Credit Suisse
BABA Alibaba
$201.61 /

-10.39 (-4.90%)

05/22/20 Goldman Sachs
Goldman Sachs keeps Buy rating on Alibaba after better than expected Q4
04/09/20 Morgan Stanley
Alibaba 'core of core' revenue recovery outlook improved, says Morgan Stanley
03/23/20 Oppenheimer
Tencent, Baidu, Alibaba attractive at current levels, says Oppenheimer
02/25/20 Goldman Sachs
Huya downgraded to Neutral on cost inflation at Goldman Sachs
SPLK Splunk
$184.26 /

+20.99 (+12.86%)

05/22/20 JPMorgan
Splunk price target raised to $190 from $174 at JPMorgan
05/22/20 Raymond James
Splunk price target raised to $185 from $140 at Raymond James
05/22/20 Oppenheimer
Splunk price target raised to $190 from $145 at Oppenheimer
05/22/20 BMO Capital
Splunk price target raised to $190 from $177 at BMO Capital
RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

05/22/20 Morgan Stanley
LiveRamp can reset expectations after guidance withdrawal, says Morgan Stanley
05/22/20 Susquehanna
LiveRamp price target raised to $60 from $50 at Susquehanna
04/27/20 Needham
LiveRamp price target lowered to $57 from $70 at Needham
04/21/20 Berenberg
LiveRamp initiated with a Buy at Berenberg
ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

05/22/20 SunTrust
e.l.f. Beauty price target raised to $20 from $15 at SunTrust
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
03/18/20 DA Davidson
e.l.f. Beauty price target lowered to $12 from $24.50 at DA Davidson
02/06/20 Piper Sandler
e.l.f. Beauty price target raised to $23 from $19 at Piper Sandler
AMRN Amarin
$7.16 /

-0.125 (-1.72%)

05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
05/22/20 Cantor Fitzgerald
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

05/22/20 Cantor Fitzgerald
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald
04/28/20 Barclays
Hikma price target raised to 2,200 GBp from 1,950 GBp at Barclays
04/23/20 Goldman Sachs
Hikma Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
ICPT Intercept
$79.55 /

-12 (-13.11%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
SPLK Splunk
$184.26 /

+20.99 (+12.86%)

RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

SPLK Splunk
$184.26 /

+20.99 (+12.86%)

RAMP LiveRamp
$48.51 /

+9.81 (+25.35%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

ELF e.l.f. Beauty
$16.46 /

+1.9 (+13.05%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

SPLK Splunk
$184.26 /

+20.99 (+12.86%)

NVDA Nvidia
$359.38 /

+8.37 (+2.38%)

ICPT Intercept
$79.55 /

-12 (-13.11%)

IBM IBM
$117.75 /

-1.37 (-1.15%)

HPE HP Enterprise
$9.21 /

-1.14 (-11.01%)

DE Deere
$144.73 /

+1.92 (+1.34%)

BABA Alibaba
$201.61 /

-10.39 (-4.90%)

AMRN Amarin
$7.16 /

-0.125 (-1.72%)

Options
Amarin call volume above normal and directionally bullish » 11:25
05/22/20
05/22
11:25
05/22/20
11:25
AMRN

Amarin

$7.17 /

-0.115 (-1.58%)

Bullish option flow…

Bullish option flow detected in Amarin with 14,504 calls trading, 1.6x expected, and implied vol increasing over 5 points to 85.64%. 5/22 weekly 7.5 calls and 5/29 weekly 8 calls are the most active options, with total volume in those strikes near 4,100 contracts. The Put/Call Ratio is 0.17. Earnings are expected on July 29th.

ShowHide Related Items >><<
AMRN Amarin
$7.17 /

-0.115 (-1.58%)

AMRN Amarin
$7.17 /

-0.115 (-1.58%)

05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
05/22/20 Cantor Fitzgerald
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval
AMRN Amarin
$7.17 /

-0.115 (-1.58%)

AMRN Amarin
$7.17 /

-0.115 (-1.58%)

AMRN Amarin
$7.17 /

-0.115 (-1.58%)

AMRN Amarin
$7.17 /

-0.115 (-1.58%)

Recommendations
Roth Capital says buy Amarin as at-risk generic launch unlikely » 11:04
05/22/20
05/22
11:04
05/22/20
11:04
AMRN

Amarin

$7.20 /

-0.085 (-1.17%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

While Amarin (AMRN) is…

While Amarin (AMRN) is trading lower after Hikma Pharmaceuticals (HKMPF) announced the first FDA approval for a generic Vascepa, there is a low likelihood of an at-risk launch, Roth Capital analyst Yasmeen Rahimi tells investors in a research note. When combined with Amarin's "position of strength in its expedited appeals argument," the selloff today presents a buying opportunity, contends the analyst. Rahimi sees a low likelihood of an at-risk launch due to the potential liabilities on an appeal loss as well as the complexity of manufacturing. The analyst keeps a Buy rating on Amarin with a $31 price target. The stock is well off its lows in morning trading but remains down 5c to $7.23.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.20 /

-0.085 (-1.17%)

AMRN Amarin
$7.20 /

-0.085 (-1.17%)

05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
05/22/20 Cantor Fitzgerald
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval
05/22/20 Cantor Fitzgerald
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

04/28/20 Barclays
Hikma price target raised to 2,200 GBp from 1,950 GBp at Barclays
04/23/20 Goldman Sachs
Hikma Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
04/16/20 Jefferies
Hikma Pharmaceuticals downgraded to Hold from Buy at Jefferies
AMRN Amarin
$7.20 /

-0.085 (-1.17%)

AMRN Amarin
$7.20 /

-0.085 (-1.17%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.20 /

-0.085 (-1.17%)

AMRN Amarin
$7.20 /

-0.085 (-1.17%)

Recommendations
Roth sees low likelihood of at-risk generic launch of Vascepa  10:53
05/22/20
05/22
10:53
05/22/20
10:53
AMRN

Amarin

$7.30 /

+0.015 (+0.21%)

 
ShowHide Related Items >><<
AMRN Amarin
$7.30 /

+0.015 (+0.21%)

AMRN Amarin
$7.30 /

+0.015 (+0.21%)

05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
05/22/20 Cantor Fitzgerald
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval
05/22/20 Cantor Fitzgerald
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald
05/14/20 H.C. Wainwright
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
AMRN Amarin
$7.30 /

+0.015 (+0.21%)

AMRN Amarin
$7.30 /

+0.015 (+0.21%)

AMRN Amarin
$7.30 /

+0.015 (+0.21%)

AMRN Amarin
$7.30 /

+0.015 (+0.21%)

Recommendations
Amarin selloff today a buying opportunity, says Roth Capital  10:52
05/22/20
05/22
10:52
05/22/20
10:52
AMRN

Amarin

$7.31 /

+0.02 (+0.27%)

 
ShowHide Related Items >><<
AMRN Amarin
$7.31 /

+0.02 (+0.27%)

AMRN Amarin
$7.31 /

+0.02 (+0.27%)

05/22/20 Cantor Fitzgerald
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval
05/22/20 Cantor Fitzgerald
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald
05/14/20 H.C. Wainwright
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
05/05/20 Northland
Northland starts Amarin at Outperform amid 'major paradigm shift'
AMRN Amarin
$7.31 /

+0.02 (+0.27%)

AMRN Amarin
$7.31 /

+0.02 (+0.27%)

AMRN Amarin
$7.31 /

+0.02 (+0.27%)

AMRN Amarin
$7.31 /

+0.02 (+0.27%)

Recommendations
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval » 09:28
05/22/20
05/22
09:28
05/22/20
09:28
AMRN

Amarin

$7.29 /

-0.175 (-2.35%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen noted that Hikma announced FDA approval for a generic version of Amarin's Vascepa but that its press release did not confirm Hikma's next steps. However, she thinks "it sounded like" Hikma would wait on the patent appeal decision before launching. While the headlines will be viewed negatively and Amarin shares will likely trade down today, Chen said it would be unlikely for a generic drug company to launch at risk with a potential decision as early as the end of this year. As she continues to believe that Amarin will prevail in its appeal of the decision, and notes that the supply chain for Vascepa is complex and it is not clear generics could launch a meaningful amount of drug into the market, she remains positive on Amarin and reaffirms her Overweight rating on the shares.

ShowHide Related Items >><<
AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

05/22/20 Cantor Fitzgerald
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald
05/14/20 H.C. Wainwright
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
05/05/20 Northland
Northland starts Amarin at Outperform amid 'major paradigm shift'
05/05/20
Fly Intel: Top five analyst initiations
AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

On The Fly
Fly Intel: Pre-market Movers » 08:54
05/22/20
05/22
08:54
05/22/20
08:54
MRNA

Moderna

$67.01 /

-6.46 (-8.79%)

, DE

Deere

$142.81 /

+0.51 (+0.36%)

, PDD

Pinduoduo

$60.04 /

-0.89 (-1.46%)

, ICLK

iClick Interactive Asia

$5.41 /

+0.31 (+6.08%)

, TLGT

Teligent

$0.42 /

+0.0125 (+3.06%)

, PANW

Palo Alto Networks

$229.36 /

-4.89 (-2.09%)

, NVDA

Nvidia

$351.01 /

-7.78 (-2.17%)

, FL

Foot Locker

$29.37 /

+1.05 (+3.71%)

, INTU

Intuit

$290.30 /

-0.4 (-0.14%)

, HPE

HP Enterprise

$10.35 /

+0.07 (+0.68%)

, SNDX

Syndax

$20.51 /

+0.34 (+1.69%)

, ROKU

Roku

$114.76 /

-2.3 (-1.96%)

, AMRN

Amarin

$7.29 /

-0.175 (-2.35%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
TLGT Teligent
$0.42 /

+0.0125 (+3.06%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

ROKU Roku
$114.76 /

-2.3 (-1.96%)

PDD Pinduoduo
$60.04 /

-0.89 (-1.46%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

MRNA Moderna
$67.01 /

-6.46 (-8.79%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

ICLK iClick Interactive Asia
$5.41 /

+0.31 (+6.08%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

FL Foot Locker
$29.37 /

+1.05 (+3.71%)

DE Deere
$142.81 /

+0.51 (+0.36%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

MRNA Moderna
$67.01 /

-6.46 (-8.79%)

05/20/20 Morgan Stanley
Moderna price target raised to $90 from $37 at Morgan Stanley
05/19/20 Piper Sandler
Piper trims Moderna target to $100 on capital raise dilution
05/19/20 BMO Capital
Moderna price target raised to $112 from $83 at BMO Capital
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
DE Deere
$142.81 /

+0.51 (+0.36%)

05/22/20 Goldman Sachs
Goldman Sachs sees Deere shares outperforming today after earnings
05/20/20 Citi
Deere price target lowered to $145 from $155 at Citi
04/20/20 OTR Global
Farm Equipment Manufacturers downgraded to Negative at OTR Global
04/20/20 Stephens
USDA aid package a positive for Large Ag, says Stephens
PDD Pinduoduo
$60.04 /

-0.89 (-1.46%)

05/22/20 CLSA
Pinduoduo price target raised to $72 from $46.50 at CLSA
05/20/20 BofA
Pinduoduo downgraded to Neutral from Buy at BofA
04/29/20 KeyBanc
Pinduoduo price target raised to $65 from $50 at KeyBanc
04/20/20 Credit Suisse
Pinduoduo upgraded to Outperform from Neutral at Credit Suisse
ICLK iClick Interactive Asia
$5.41 /

+0.31 (+6.08%)

05/22/20 Roth Capital
Roth ups iClick target to $7.50, remains buyer after Q1 report
03/31/20 Roth Capital
iClick Interactive Asia Q4 pre-announcement 'in-line,' says Roth Capital
01/27/20 Alliance Global Partners
iClick Interactive Asia initiated with a Buy at Alliance Global Partners
12/05/19 Jefferies
iClick Interactive Asia initiated with a Buy at Jefferies
TLGT Teligent
$0.42 /

+0.0125 (+3.06%)

10/03/19
Fly Intel: Top five analyst downgrades
10/03/19 Raymond James
Teligent downgraded at Raymond James following strategic review announcement
10/03/19 Raymond James
Teligent downgraded to Market Perform from Outperform at Raymond James
PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

05/22/20 BMO Capital
Palo Alto Networks price target raised to $260 from $230 at BMO Capital
05/22/20 RBC Capital
Palo Alto Networks price target raised to $248 from $225 at RBC Capital
05/22/20 Northland
Palo Alto Networks price target raised to $285 from $274 at Northland
05/22/20 Oppenheimer
Palo Alto Networks price target raised to $265 from $225 at Oppenheimer
NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

05/22/20 JPMorgan
Nvidia price target raised to $405 from $305 at JPMorgan
05/22/20 Rosenblatt
Nvidia price target raised to $400 from $340 at Rosenblatt
05/22/20 Raymond James
Nvidia price target raised to $370 from $330 at Raymond James
05/22/20 Craig-Hallum
Nvidia price target raised to $335 from $300 at Craig-Hallum
FL Foot Locker
$29.37 /

+1.05 (+3.71%)

05/20/20 Susquehanna
Foot Locker price target raised to $28 from $20 at Susquehanna
05/19/20 Pivotal Research
Foot Locker price target lowered to $37 from $45 at Pivotal Research
05/15/20 Deutsche Bank
Foot Locker price target lowered to $27 from $36 at Deutsche Bank
05/08/20 Raymond James
Foot Locker price target lowered to $30 from $50 at Raymond James
INTU Intuit
$290.30 /

-0.4 (-0.14%)

05/22/20 RBC Capital
Intuit price target raised to $315 from $280 at RBC Capital
05/22/20 Guggenheim
Guggenheim ups Intuit price target to $320 with odds of worst case diminishing
05/22/20 Citi
Intuit price target raised to $292 from $272 at Citi
05/22/20 Wells Fargo
Intuit price target raised to $330 from $310 at Wells Fargo
HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 Raymond James
HP Enterprise downgraded to Market Perform from Outperform at Raymond James
05/22/20 Morgan Stanley
Second quarter 'not yet a bottom' for HP Enterprise, says Morgan Stanley
05/22/20 Citi
HP Enterprise earnings call leaves more questions than answers, says Citi
SNDX Syndax
$20.51 /

+0.34 (+1.69%)

05/22/20 H.C. Wainwright
Syndax downgraded to Neutral from Buy at H.C. Wainwright
05/22/20 H.C. Wainwright
Syndax downgraded to Neutral from Buy at H.C. Wainwright
05/22/20
Fly Intel: Top five analyst upgrades
05/22/20 Citi
Syndax upgraded to Buy from Neutral at Citi
ROKU Roku
$114.76 /

-2.3 (-1.96%)

05/22/20 Stephens
Roku downgraded to Equal Weight on worries about TCL at Stephens
05/22/20 Stephens
Roku downgraded to Equal Weight from Overweight at Stephens
05/08/20 Susquehanna
Roku price target lowered to $145 from $170 at Susquehanna
AMRN Amarin
$7.29 /

-0.175 (-2.35%)

05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
05/22/20 Cantor Fitzgerald
Cantor Fitzgerald still positive on Amarin despite Hikma's generic approval
TLGT Teligent
$0.42 /

+0.0125 (+3.06%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

ROKU Roku
$114.76 /

-2.3 (-1.96%)

PDD Pinduoduo
$60.04 /

-0.89 (-1.46%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

MRNA Moderna
$67.01 /

-6.46 (-8.79%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

ICLK iClick Interactive Asia
$5.41 /

+0.31 (+6.08%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

FL Foot Locker
$29.37 /

+1.05 (+3.71%)

DE Deere
$142.81 /

+0.51 (+0.36%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

  • 19
    May
ROKU Roku
$114.76 /

-2.3 (-1.96%)

PDD Pinduoduo
$60.04 /

-0.89 (-1.46%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

MRNA Moderna
$67.01 /

-6.46 (-8.79%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

FL Foot Locker
$29.37 /

+1.05 (+3.71%)

DE Deere
$142.81 /

+0.51 (+0.36%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

TLGT Teligent
$0.42 /

+0.0125 (+3.06%)

SNDX Syndax
$20.51 /

+0.34 (+1.69%)

ROKU Roku
$114.76 /

-2.3 (-1.96%)

PDD Pinduoduo
$60.04 /

-0.89 (-1.46%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

MRNA Moderna
$67.01 /

-6.46 (-8.79%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

FL Foot Locker
$29.37 /

+1.05 (+3.71%)

DE Deere
$142.81 /

+0.51 (+0.36%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

ROKU Roku
$114.76 /

-2.3 (-1.96%)

PDD Pinduoduo
$60.04 /

-0.89 (-1.46%)

PANW Palo Alto Networks
$229.36 /

-4.89 (-2.09%)

NVDA Nvidia
$351.01 /

-7.78 (-2.17%)

MRNA Moderna
$67.01 /

-6.46 (-8.79%)

INTU Intuit
$290.30 /

-0.4 (-0.14%)

HPE HP Enterprise
$10.35 /

+0.07 (+0.68%)

FL Foot Locker
$29.37 /

+1.05 (+3.71%)

DE Deere
$142.81 /

+0.51 (+0.36%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

Hot Stocks
Amarin falls 13% to $6.30 after FDA grants approval to Vascepa generic  07:51
05/22/20
05/22
07:51
05/22/20
07:51
AMRN

Amarin

$7.29 /

-0.175 (-2.35%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

05/22/20 Cantor Fitzgerald
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald
05/14/20 H.C. Wainwright
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
05/05/20 Northland
Northland starts Amarin at Outperform amid 'major paradigm shift'
05/05/20
Fly Intel: Top five analyst initiations
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

04/28/20 Barclays
Hikma price target raised to 2,200 GBp from 1,950 GBp at Barclays
04/23/20 Goldman Sachs
Hikma Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
04/16/20 Jefferies
Hikma Pharmaceuticals downgraded to Hold from Buy at Jefferies
AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

Recommendations
COVID-19 trial validation of Vascepa's science, says Cantor Fitzgerald » 07:51
05/22/20
05/22
07:51
05/22/20
07:51
AMRN

Amarin

$7.29 /

-0.175 (-2.35%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen views the clinical trial investigating the effects of Vascepa on inflammatory biomarkers and other patient outcomes in individuals with COVID-19 as a validation of the science behind Amarin's (AMRN) drug. The pilot study may provide more information on whether, how, and if icosapent ethyl has biological activity that could have beneficial effects in mitigating severity in COVID-19 infection, Chen tells investors in a research note. The analyst believes multiple mechanisms of action associated with Vascepa from clinical and mechanistic studies support the rationale to study its effects in patients with the COVID-19 infection. Chen keeps an Overweight rating on Amarin shares with a $35 price target. The stock in premarket trading is down 11% to $6.32 after Hikma Pharmaceuticals (HKMPF) announced overnight that it received approval from the Food and Drug Administration for its Icosapent Ethyl Capsules, the generic equivalent to Vascepa.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

05/14/20 H.C. Wainwright
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
05/05/20 Northland
Northland starts Amarin at Outperform amid 'major paradigm shift'
05/05/20
Fly Intel: Top five analyst initiations
05/05/20 Northland
Amarin initiated with an Outperform at Northland
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

04/28/20 Barclays
Hikma price target raised to 2,200 GBp from 1,950 GBp at Barclays
04/23/20 Goldman Sachs
Hikma Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
04/16/20 Jefferies
Hikma Pharmaceuticals downgraded to Hold from Buy at Jefferies
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

Hot Stocks
Hikma receives FDA approval for generic of Amarin's Vascepa » 05:52
05/22/20
05/22
05:52
05/22/20
05:52
AMRN

Amarin

$7.29 /

-0.175 (-2.35%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Hikma Pharmaceuticals…

Hikma Pharmaceuticals (HKMPF) announced overnight that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA has received approval from the Food and Drug Administration for its Icosapent Ethyl Capsules, the generic equivalent to Amarin's (AMRN) Vascepa. In March 2020, the United States District Court for the District of Nevada invalidated six Vascepa patents owned by Amarin. The district court decision is currently being appealed. Brian Hoffmann, Hikma's President of Generics said, "The approval for our generic version of Vascepa is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need." Shares of Amarin closed Thursday down 18c to $7.28.

ShowHide Related Items >><<
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

05/14/20 H.C. Wainwright
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
05/05/20 Northland
Northland starts Amarin at Outperform amid 'major paradigm shift'
05/05/20
Fly Intel: Top five analyst initiations
05/05/20 Northland
Amarin initiated with an Outperform at Northland
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

04/28/20 Barclays
Hikma price target raised to 2,200 GBp from 1,950 GBp at Barclays
04/23/20 Goldman Sachs
Hikma Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
04/16/20 Jefferies
Hikma Pharmaceuticals downgraded to Hold from Buy at Jefferies
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

AMRN Amarin
$7.29 /

-0.175 (-2.35%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.